SCHEMBL3537237

SCHEMBL3537237

CCCCc1nc(-c2ccc(C(F)(F)F)cc2)sc1CCOc1ccc(-c2noc(=O)[nH]2)c(Cl)c1

nearest known ligand 0.39

Predicted protein targets (top 11)

geneUniProtsupporting neighboursconfidence
PLA2G2A P14555 11/20 0.39
PTPN1 P18031 2/20 0.39
GCGR P47871 1/20 0.38
PLA2G10 O15496 4/20 0.37
PLA2G1B P04054 3/20 0.37
PLA2G5 P39877 3/20 0.37
PPARG P37231 2/20 0.37
PPARD Q03181 1/20 0.36
PPARA Q07869 1/20 0.36
ATP4A P20648 1/20 0.36
ATP4B P51164 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3541315 0.93 PPARD (0.41) PLA2G2APPARGPPARDPPARA
SCHEMBL3534251 0.87 PPARA (0.42) PTPN1PPARGPPARDPPARA
SCHEMBL3537385 0.86 PPARD (0.41) PPARGPPARDPPARA
SCHEMBL3538288 0.85 PPARD (0.41) PPARGPPARDPPARA
SCHEMBL3538137 0.85 PPARD (0.42) PLA2G2APLA2G10PLA2G1BPLA2G5PPARG
SCHEMBL3539539 0.85 PPARD (0.45) PLA2G2APLA2G10PLA2G1BPLA2G5PPARG
SCHEMBL3537006 0.85 PPARD (0.47) PLA2G2APLA2G10PLA2G1BPLA2G5PPARG
SCHEMBL3536049 0.84 PPARD (0.42) PLA2G2APLA2G10PLA2G1BPLA2G5PPARG
SCHEMBL13787896 0.84 PPARD (0.41) PLA2G2APLA2G10PLA2G1BPLA2G5PPARG
SCHEMBL3537447 0.84 PPARD (0.41) PLA2G2APLA2G10PLA2G1BPLA2G5PPARG

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7709509-B2 Oxadiazolones and derivatives thereof as peroxisome proliferator-activated receptor (PPAR) delta agonists SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) 2010-05-04 US disclosed
US-7709509-B2 Oxadiazolones and derivatives thereof as peroxisome proliferator-activated receptor (PPAR) delta agonists SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) 2010-05-04 US disclosed
US-7709509-B2 Oxadiazolones and derivatives thereof as peroxisome proliferator-activated receptor (PPAR) delta agonists SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) 2010-05-04 US disclosed
EP-2083006-A1 Oxadiazolones, processes for their preparation and their use as pharmaceuticals Sanofi-Aventis Deutschland GmbH (DE) 2009-07-29 EP disclosed
EP-2083006-A1 Oxadiazolones, processes for their preparation and their use as pharmaceuticals Sanofi-Aventis Deutschland GmbH (DE) 2009-07-29 EP disclosed
EP-1740583-B1 OXADIAZOLONE DERIVATIVES AS PPAR DELTA AGONISTS SANOFI AVENTIS DEUTSCHLAND (DE) 2009-07-01 EP disclosed
US-20080262052-A1 METHODS FOR THE TREATMENT OF METABOLIC AND GLUCOSE UTILIZATION DISORDERS THROUGH THE ADMINISTRATION OF OXADIAZOLONES AND DERIVATIVES THEREOF AS PEROXISOME PROLIFERATOR - ACTIVATED RECEPTOR (PPAR) DELTA AGONISTS SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) 2008-10-23 US disclosed
US-20080262052-A1 METHODS FOR THE TREATMENT OF METABOLIC AND GLUCOSE UTILIZATION DISORDERS THROUGH THE ADMINISTRATION OF OXADIAZOLONES AND DERIVATIVES THEREOF AS PEROXISOME PROLIFERATOR - ACTIVATED RECEPTOR (PPAR) DELTA AGONISTS SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) 2008-10-23 US disclosed
US-20080262052-A1 METHODS FOR THE TREATMENT OF METABOLIC AND GLUCOSE UTILIZATION DISORDERS THROUGH THE ADMINISTRATION OF OXADIAZOLONES AND DERIVATIVES THEREOF AS PEROXISOME PROLIFERATOR - ACTIVATED RECEPTOR (PPAR) DELTA AGONISTS SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) 2008-10-23 US disclosed
US-20080255212-A1 OXADIAZOLONES AND DERIVATIVES THEREOF AS PEROXISOME PROLIFERATOR - ACTIVATED RECEPTOR (PPAR) DELTA AGONISTS SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) 2008-10-16 US disclosed
US-20080255212-A1 OXADIAZOLONES AND DERIVATIVES THEREOF AS PEROXISOME PROLIFERATOR - ACTIVATED RECEPTOR (PPAR) DELTA AGONISTS SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) 2008-10-16 US disclosed
US-20080255212-A1 OXADIAZOLONES AND DERIVATIVES THEREOF AS PEROXISOME PROLIFERATOR - ACTIVATED RECEPTOR (PPAR) DELTA AGONISTS SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) 2008-10-16 US disclosed
US-20070179191-A1 OXADIAZOLONES AND DERIVATIVES THEREOF AS PPAR DELTA AGONISTS SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) 2007-08-02 US disclosed
US-20070179191-A1 OXADIAZOLONES AND DERIVATIVES THEREOF AS PPAR DELTA AGONISTS SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) 2007-08-02 US disclosed
US-20070179191-A1 OXADIAZOLONES AND DERIVATIVES THEREOF AS PPAR DELTA AGONISTS SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) 2007-08-02 US disclosed
EP-1740583-A1 OXADIAZOLONE DERIVATIVES AS PPAR DELTA AGONISTS Sanofi-Aventis Deutschland GmbH (DE) 2007-01-10 EP disclosed
WO-2005097786-A1 OXADIAZOLONE DERIVATIVES AS PPAR DELTA AGONISTS SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) 2005-10-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070179191-A1 OXADIAZOLONES AND DERIVATIVES THEREOF AS PPAR DELTA AGONISTS PPARD, PPARA, PPARG PLA2G2A 1850/4885PTPN1 930/4885GCGR 108/4885
US-20080255212-A1 OXADIAZOLONES AND DERIVATIVES THEREOF AS PEROXISOME PROLIFERATOR - ACTIVATED RECEPTOR (PPAR) DELTA AGONISTS PPARD, PPARG, PPARA PLA2G2A 1558/4885PTPN1 939/4885GCGR 42/4885
US-20080262052-A1 METHODS FOR THE TREATMENT OF METABOLIC AND GLUCOSE UTILIZATION DISORDERS THROUGH THE ADMINISTRATION OF OXADIAZOLONES AND DERIVATIVES THEREOF AS PEROXISOME PROLIFERATOR - ACTIVATED RECEPTOR (PPAR) DELTA AGONISTS PPARD, PPARG, PPARA PLA2G2A 1740/4885PTPN1 1346/4885GCGR 152/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.